NCT02180503View on ClinicalTrials.gov

Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers Including the Influence of Food on the Bioavailability of 10 mg BI 1356 BS

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

October 31, 2005

Conditions
Healthy
Interventions
DRUG

BI 1356 BS PIB - low dose

DRUG

BI 1356 BS tablet - low dose

DRUG

BI 1356 BS PIB - high dose

DRUG

BI 1356 BS tablet - high dose

DRUG

BI 1356 BS tablet - high dose with food

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02180503 - Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers Including the Influence of Food on the Bioavailability of 10 mg BI 1356 BS | Biotech Hunter | Biotech Hunter